Annovis Bio (ANVS) announced it will begin an open-label extension study in January 2026 to evaluate the long-term safety and efficacy of buntanetap in PD patients.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANVS:
- Annovis Bio Advances Long-Term Buntanetap Safety Study in Parkinson’s Disease
- Annovis Bio Receives Buy Rating Amid Promising Phase 3 Trial Results and Strategic FDA Discussions for Buntanetap
- Annovis announces FDA meeting to discuss PDD program
- Annovis Bio announces biomarker data on amyloid co-pathology in Parkinson’s
- Annovis Bio’s Strategic Advances and Insider Confidence Drive Buy Rating Amid Promising Alzheimer’s Treatment Progress